BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• 2026 is poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies

  80% confidence

• Revenues to BioNTech from the collaboration with BMS in 2026 are expected to be broadly in line with 2025

  80% confidence

• BioNTech has more than ten novel-novel combination clinical trials in its pipeline with multiple data updates expected in 2026

  80% confidence

• BioNTech anticipates a modest decline in Comirnaty revenues compared to 2025, reflecting COVID-19 vaccine market dynamics

  80% confidence

• BioNTech has more than doubled the number of Phase 2 and 3 oncology trials across key modalities within the past two years, with now more than 25 Phase 2 or 3 trials ongoing

  80% confidence

• BioNTech expects seven late-stage data readouts in 2026

  80% confidence

• BioNTech plans to initiate six additional Phase 3 clinical trials in 2026, bringing the total number of anticipated Phase 3 clinical trials to 15 by year end

  80% confidence

• 2026 will be a year when science translates into tangible results with readouts from late-stage trials and earlier trials evaluating novel-novel combinations

  80% confidence

• BioNTech expects at least 17 late-stage data readouts, including from pivotal trials, by 2030+

  80% confidence

• BioNTech does not currently anticipate the recognition of revenues from the sale of any oncology products in 2026

  80% confidence

Data points we hold from this source